These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25952493)

  • 1. Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
    Hassan MN; Waller EK
    Oncology (Williston Park); 2015 Apr; 29(4):295-6. PubMed ID: 25952493
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombocytopenia: optimizing approaches in cancer patients.
    Piatek C; Akhtari M
    Oncology (Williston Park); 2015 Apr; 29(4):297-8. PubMed ID: 25952494
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 5. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M
    Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
    Lee EJ; Seshadri M; Bussel JB
    Am J Hematol; 2021 Oct; 96(10):E373-E376. PubMed ID: 34152624
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune thrombocytopenia during childhood: new approaches to classification and management.
    Buchanan GR
    J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
    Sartori R; Candiotto L; Ruggeri M; Tagariello G
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
    Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
    Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on romiplostim and eltrombopag indirect comparison.
    Cooper K; Matcham J; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2014 Jan; 30(1):129-130. PubMed ID: 24485057
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of thrombopoietic agents.
    Rhodes E; Stasi R
    Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
    Lown R; Rhodes E; Bosworth J; Shannon MS; Stasi R
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):809-12. PubMed ID: 21326159
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing thrombocytopenia associated with cancer chemotherapy.
    Kuter DJ
    Oncology (Williston Park); 2015 Apr; 29(4):282-94. PubMed ID: 25952492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 19. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
    Gill H; Leung GM; Lopes D; Kwong YL
    Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.